<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40350">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02109523</url>
  </required_header>
  <id_info>
    <org_study_id>28/20/7200</org_study_id>
    <nct_id>NCT02109523</nct_id>
  </id_info>
  <brief_title>Improving Adherence to Medication After Coronary Artery Bypass Surgery (CABG) in Older Adults</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qazvin University Of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qazvin University Of Medical Sciences</source>
  <oversight_info>
    <authority>Iran: Ministry of Health</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coronary artery bypass grafting (CABG) surgery is often performed in elderly patients, but
      non-adherence to post-CABG guideline medications is a common and serious clinical concern in
      this age group. A recent systematic review found that higher medication adherence
      significantly improved primary and secondary prevention of coronary artery disease outcomes
      in all the included studies. Another systematic review  assessed studies published from
      1999-2009 about motivational interviews, such as implementation intention, in relation to
      cardiovascular health. They found that motivational interview was an effective means of
      changing behavior, while offering promise in improving cardiovascular health status. The
      study is aimed to investigate effectiveness of long term volitional intervention in proving
      medication adherence in the CABG patient.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>changes in Patient-reported medication Adherence to four therapies (aspirin/antiplatelet; beta blocker; statin; ACE inhibitor)</measure>
    <time_frame>changes from baseline , 6 Months, 12 months and 18 months after the intervention</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Percent of Patients Adherent to four therapies (aspirin/antiplatelet; beta blocker; statin; ACE inhibitor) Via Refill Records</measure>
    <time_frame>Changes from baseline, 6 Months, 12 months and 18 months after the intervention</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in psychological predictors of medication adherence (intention, perceived behavioral control and Self-monitoring)</measure>
    <time_frame>changes from baseline, 6 Months, 12 months and 18 months follow-up</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in action planning</measure>
    <time_frame>changes from baseline, 6 Months, 12 months and 18 months follow-up</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The number of planning strategies is used by the patients before, at baseline, six months, twelve months and eighteen months after the intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in coping planning</measure>
    <time_frame>changes from baseline, 6 Months, 12 months and 18 months follow-up</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The number of planning strategies is used by the patients before, at baseline, six months, twelve months and eighteen months after the intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in quality of life</measure>
    <time_frame>changes from baseline, 6 Months, 12 months and 18 months follow-up</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate and Myocardial Infarction</measure>
    <time_frame>changes from baseline, 6 Months, 12 months and 18 months follow-up</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Beliefs about Medications</measure>
    <time_frame>changes from baseline, 6 Months, 12 months and 18 months follow-up</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Illness Perceptions</measure>
    <time_frame>changes from baseline, 6 Months, 12 months and 18 months follow-up</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in habit strength</measure>
    <time_frame>changes from baseline, 6 Months, 12 months and 18 months follow-up</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Patient's habits on  medications use before, at baseline, six months, twelve months and eighteen months after the intervention</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">172</enrollment>
  <condition>Coronary Artery Bypass Grafting (CABG) Surgery</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients enrolled in the intervention arm will receive two educational sessions  on the importance of medication and barriers to adherence</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The usual care group received routine discharge counseling performed by the cardiologists and nurses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Motivational Interviewing (MI</intervention_name>
    <description>In order to facilitate behavior change by the patients a Motivational Interviewing (MI) is designed to resolve patient ambivalence about change. The interview is conducted individually face to face by an experienced trainer. The MI was used a semi-structured format and lasting for 40 minutes for a single session (the first session). The counselors ask participants to express what they want to discuss about. Moreover, counselors ask some questions which were important in the patient's life (e.g. what they will do after discharge, what they think about their life). These questions help the counselors to make a confident relationship between the counselors and patients. Furthermore, the counselors try to elicit adolescent's concerns on their current situations by asking some questions (What concerns you about your current situation? What are some reasons you might see for making a change? How do you feel about your treatment?)</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>facilitate behavior change</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>volitional intervention</intervention_name>
    <description>The second session will be based on action and coping planning strategies, according to the theoretical principles of implementation intention (Sniehotta et al. 2006), a self-regulatory strategy that matches concrete responses to possible future situations. Our intervention consists of two face-to-face meetings (at baseline, during the person's visit to the clinic). With the help of one of the authors, at the baseline interview, participants in the intervention group elaborate up to three action plans about when, where and how they intended to take their medication prescribed for cardioprotection and symptom relief of CAD. Similarly, participants identify up to three barriers to take the medication. Then, one or more strategies to overcome each barrier were identified, to accomplish the coping planning strategy. The number of barriers is limited to three because many of the participants are older adults and would have difficulty in memorizing too many strategies (Scholz et al. 2005).</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Planning intervention</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Routine discharge counseling</intervention_name>
    <arm_group_label>Usual Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 65 years or older

          -  Undergoing Elective/subacute multivessel CABG

          -  Able to give informed consent

        Exclusion Criteria:

          -  Pregnant

          -  Already using Dosette boxes (or similar) to improve their medication adherence

          -  Currently enrolled in another clinical trial

          -  Unable to attend required follow-up visits

          -  Mini Mental Status Examination (MMSE) less than 20

          -  Significant dysphasia

          -  Concomitant surgery

          -  Myocardial infarction &lt;48h of surgery

          -  Known platelet disease

          -  Allergic to aspirin

          -  Alcohol or narcotics abuse

          -  Geographically not available for follow up

          -  Ongoing bleeding

          -  Missing written consent

          -  Emergency surgery

          -  Severe kidney disease (creatinine clearance &lt; 30 ml/min)

          -  Oxygen-dependent chronic obstructive pulmonary disease

          -  Active hepatitis

          -  Significant hepatic failure

          -  Prior peptic ulcerâ€¢ Platelet count &lt; 150 E9

          -  Patient has terminal condition and may not survive until 6-month follow-up

          -  Patient is a known participant in other RC studies

          -  The inability to read and write Persian/Farsi

          -  Participants who are not responsible for their own medication
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amir H Pakpour, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qazvin University Of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amir Pakpour</last_name>
    <phone>+98-281-3338127</phone>
    <email>Pakpour_Amir@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Qazvin University of Medical Sciences</name>
      <address>
        <city>Qazvin</city>
        <zip>3419759811</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amir H Pakpour, PhD</last_name>
      <phone>982813338127</phone>
      <email>Pakpour_Amir@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 9, 2014</lastchanged_date>
  <firstreceived_date>April 1, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Qazvin University Of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Amir H Pakpour</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
